Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of tisagenlecleucel (CTL019) in adult relapsed/refractory follicular lymphoma
jRCT1080224541Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in follicular lymphoma (FL), sponsored by Novartis. Started Jan 2019; status: completed.
02
Drugs
tisagenlecleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT1080224541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224541.